Category: News

NovaBay Pharmaceuticals Reports 2015 Fourth Quarter and Full Year Financial Results

EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical Company focusing on commercializing its prescription Avenova® Lid and Lash Cleanser for the domestic eye care market, reports financial results for the three and 12 months ended December 31, 2015, and provides a business update. Fourth Quarter 2015 versus Third Quarter 2015 Avenova Highlights 41% increase in sales to a record $1.6 million 29% increase in the number of optometrists and ophtha


Global Contact Lenses & Intraocular Lenses Market – Expected to Grow to US$ 20,050.9 Million by 2019 at a CAGR of 8.4% – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/nhqn5v/global_contact) has announced the addition of the “Global Contact Lenses & Intraocular Lenses Market Assessment & Forecast: 2015-2019” report to their offering. The North American market is anticipated to continue leading in terms of value due to ease of availability, higher awareness and diagnosis, greater number of ophthalmologists and optometrists per 1000 people as compared to other regi


First Patients in Presbia Microlens FDA Study Complete 12-Month Postoperative Visits

DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, announced today that all subjects treated as part of the first stage of its U.S. Food and Drug Administration (FDA) pivotal study completed their 12-month postoperative visits, a significant milestone in the FDA approval process of its Presbia Flexivue Microlens™. The Presbia Flexivue Microlens is a revolutionary optical lens implant for treating presbyopia, the age-related l


ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015

SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2015. “2015 was highlighted by the filing of our NUPLAZID™ (pimavanserin) New Drug Application for Parkinson’s disease psychosis and the designation of Priority Review b